Study design and clinical evidence in mRCC

Can we save axitinib as a first-line therapy?

Roberto Iacovelli Department of Medical Oncology; Fondazione IRCSS Istituto Nazionale Tumori; Milan, Italy; Department of Radiology, Oncology and Human Pathology; Sapienza University of Rome; Rome, ItalyCorrespondence[email protected]

Elena Verzoni Department of Medical Oncology; Fondazione IRCSS Istituto Nazionale Tumori; Milan, Italy

Filippo Maria De Braud Department of Medical Oncology; Fondazione IRCSS Istituto Nazionale Tumori; Milan, Italy

Giuseppe Procopio Department of Medical Oncology; Fondazione IRCSS Istituto Nazionale Tumori; Milan, Italy

References

Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, Rosbrook B, Chen C, Kim S, Vogelzang NJ. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013; 14:1287 - 94; http://dx.doi.org/10.1016/S1470-2045(13)70465-0; PMID: 24206640
PubMed Web of Science ®Google Scholar
Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931 - 9; http://dx.doi.org/10.1016/S0140-6736(11)61613-9; PMID: 22056247
PubMed Web of Science ®Google Scholar
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al, TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125 - 34; http://dx.doi.org/10.1056/NEJMoa060655; PMID: 17215530
PubMed Web of Science ®Google Scholar
Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:1280 - 9; http://dx.doi.org/10.1200/JCO.2008.19.3342; PMID: 19171708
PubMed Web of Science ®Google Scholar
Manager R. (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. Available at: http://ims.cochrane.org/revman/download
Google Scholar
Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061 - 8; http://dx.doi.org/10.1200/JCO.2009.23.9764; PMID: 20100962
PubMed Web of Science ®Google Scholar
Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, Tomczak P, Lyulko O, Alyasova A, Harza M, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013; 31:3791 - 9; http://dx.doi.org/10.1200/JCO.2012.47.4940; PMID: 24019545
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Study design and clinical evidence in mRCC

Can we save axitinib as a first-line therapy?

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Study design and clinical evidence in mRCC

Can we save axitinib as a first-line therapy?

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date